All In Biotech

Free tool

FAERS Monitor: Xiidra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208073 or its brand name (Xiidra, Lifitegrast). Reports on generic versions are filed under their own applications.

Reports

16,505

Serious

2,977

18% of reports

Hospitalization

678

Death reported

298

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye irritation2,780
  • vision blurred2,679
  • drug ineffective1,629
  • eye pain1,460
  • instillation site pain1,283
  • dry eye1,187
  • dysgeusia1,118
  • instillation site reaction1,019
  • ocular hyperaemia707
  • lacrimation increased636
  • headache629
  • visual impairment587
  • product dose omission issue454
  • eye pruritus446
  • eye discharge403

Reports by year received

View as table
YearReports
20154
2016630
20171,846
20181,538
20191,189
20201,976
20212,129
20222,489
20231,922
20241,097
2025985
2026700

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,654 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
instillation site reactionSignal1,01918293.514388.91,212,975
instillation site painSignal1,2831366.21264.6844,227
eye irritationSignal2,78064.662.4166,117
eye dischargeSignal40351.446.619,097
eye painSignal1,46033.832.245,395
dry eyeSignal1,18731.029.333,713
lacrimation increasedSignal63627.425.315,820
vision blurredSignal2,67925.324.561,786
dysgeusiaSignal1,11819.518.419,328
ocular hyperaemiaSignal70719.317.912,064
eye pruritusSignal44617.115.66,679
visual impairmentSignal5876.15.62,478
product dose omission issue4542.01.8218
drug ineffective1,6291.61.5365
headache6291.31.239

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.